GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (NAS:PHAR) » Definitions » Ending Cash Position

PHAR (Pharming Group) Ending Cash Position : $54.9 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Pharming Group Ending Cash Position?

Pharming Group's Ending Cash Position for the quarter that ended in Dec. 2024 was $54.9 Mil.

Pharming Group's quarterly Ending Cash Position increased from Jun. 2024 ($47.1 Mil) to Sep. 2024 ($60.7 Mil) but then declined from Sep. 2024 ($60.7 Mil) to Dec. 2024 ($54.9 Mil).

Pharming Group's annual Ending Cash Position declined from Dec. 2022 ($207.3 Mil) to Dec. 2023 ($61.7 Mil) and declined from Dec. 2023 ($61.7 Mil) to Dec. 2024 ($54.9 Mil).

Pharming Group Ending Cash Position Historical Data

The historical data trend for Pharming Group's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Ending Cash Position Chart

Pharming Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 205.16 191.92 207.34 61.74 54.94

Pharming Group Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.74 51.89 47.14 60.66 54.94

Pharming Group Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Pharming Group's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=61.741+-6.797
=54.9

Pharming Group's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=60.662+-5.718
=54.9

Pharming Group Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Pharming Group's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharming Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (NAS:PHAR) » Definitions » Ending Cash Position
Comparable Companies
XAMS:VVY XAMS:BAI XAMS:GLPG VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270 SMMT UTHR INSM XKRX:196170 RPRX OCSE:GMAB INCY
Traded in Other Exchanges
PHGUF:USA PHARM:Netherlands PHARMa:UK 0QCO:UK PHGN:Germany
Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Website
https://www.pharming.com
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.